4qA特异性远端D4Z4低甲基化与面肩肱型肌营养不良症疾病严重程度及进展的相关性
这项在中国福建神经医学中心开展的21年回顾性观察队列研究,对823例经基因确诊的FSHD1患者和341例健康对照进行焦磷酸测序检测远端D4Z4重复单元10个CpG甲基化水平。结果显示CpG6甲基化可区分患者与对照、症状性与无症状患者及有无下肢受累,低甲基化组下肢受累比例更高且独立行走丧失风险更高。
要点
- CpG6甲基化水平可区分FSHD1患者与健康对照,AUC(95%CI)为0.9684(0.9584-0.9785)。
- CpG6甲基化越低,临床评分越高、发病年龄越早。
- LM1组独立行走丧失风险较HM组更高,HR(95%CI)为3.523(1.565-7.930)。
核心结论
- 4q35远端D4Z4低甲基化与FSHD1疾病严重程度及下肢受累进展相关。
研究设计与样本
- 21年回顾性观察队列研究,在中国福建神经医学中心开展,纳入823例经基因确诊的FSHD1患者和341例健康对照。
- 采用亚硫酸氢盐测序评估远端D4Z4重复单元10个CpG甲基化水平,按甲基化百分比四分位数将患者分为LM1、LM2、LM3和HM四组。
- 基线及随访时评估下肢运动功能,采用FSHD临床评分、年龄校正临床严重度量表和改良Rankin量表。
主要发现
- 823例FSHD1患者10个CpG甲基化水平均显著低于341例健康对照。
- CpG6甲基化区分FSHD1与健康对照、症状性与无症状/未受累患者、有无下肢受累的AUC(95%CI)分别为0.9684(0.9584-0.9785)、0.7417(0.6903-0.7931)、0.6386(0.5816-0.6956)。
- CpG6甲基化越低与临床评分越高(r=-0.392)、年龄校正临床严重度量表越高(r=-0.432)及首次肌无力发病年龄越早(r=0.297)相关。
- LM1、LM2、LM3和HM组下肢受累比例分别为52.9%、44.2%、36.9%和23.4%,下肢受累发病年龄分别为20、26.5、25和26.5岁。
- 校正性别、检查年龄、D4Z4重复单元数和4qA/B单体型后,LM1、LM2、LM3组独立行走丧失风险更高,HR(95%CI)分别为3.523(1.565-7.930)、3.356(1.458-7.727)和2.956(1.245-7.020)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The objective of this study was to examine whether the regional methylation levels at the most distal D4Z4 repeat units (RU) in the 4qA-permissive haplotype were associated with disease severity and progression in facioscapulohumeral muscular dystrophy type 1 (FSHD1). METHODS: This 21-year, retrospective, observational cohort study was conducted at the Fujian Neuromedical Center (FNMC) in China. Methylation levels of the most distal D4Z4 RU, including 10 CpGs, were assessed in all participants by bisulfite sequencing. Patients with FSHD1 were stratified into 4 groups based on methylation percentage quartiles, including LM1 (low methylation), LM2 (low to intermediate methylation), LM3 (intermediate to high methylation), and highest methylation (HM) levels. Patients received evaluations of motor function focusing on lower extremity (LE) progression at baseline and in follow-ups. FSHD clinical score (CS), age-corrected clinical severity scale (ACSS), and modified Rankin scale were used to assess motor function. RESULTS: The methylation levels of the 10 CpGs were significantly lower in all 823 patients with genetically confirmed FSHD1 than in 341 healthy controls (HCs). CpG6 methylation levels could distinguish the following: (1) patients with FSHD1 from HCs; (2) symptomatic from asymptomatic/unaffected patients; (3) patients with LE involvement from those without LE involvement, with AUCs (95% CI) of 0.9684 (0.9584-0.9785), 0.7417 (0.6903-0.7931), and 0.6386 (0.5816-0.6956), respectively. Lower CpG6 methylation levels were correlated with higher CS (r = -0.392), higher ACSS (r = -0.432), and earlier onset age of first-ever muscle weakness (r = 0.297). For the LM1, LM2, LM3, and HM groups, the respective proportions of LE involvement were 52.9%, 44.2%, 36.9%, and 23.4%; and onset ages of LE involvement were 20, 26.5, 25, and 26.5 years. Cox regression analysis-adjusted for sex, age at examination, D4Z4 RU, and 4qA/B haplotype-showed that the LM1, LM2, and LM3 groups (i.e., groups with lower methylation levels) had a higher risk of independent ambulation loss, with HRs (95% CI) of 3.523 (1.565-7.930), 3.356 (1.458-7.727), and 2.956 (1.245-7.020), respectively. DISCUSSION: 4q35 distal D4Z4 hypomethylation is correlated with disease severity and progression to lower extremity involvement.
引用
- Zheng F, Qiu L, Chen L, et al. Association of 4qA-Specific Distal D4Z4 Hypomethylation With Disease Severity and Progression in Facioscapulohumeral Muscular Dystrophy. Neurology. 2023. PMID: 37225433. doi:10.1212/WNL.0000000000207418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。